Labs/Biomarkers

Prediction of PsA in PSO pts: does it work? First predictive model using mainly clinical data and labs extracted from primary care Performs well in the cohort it was trained w/ but not in validation cohort. Often an issue with prediction models! Needs more granularity than https://t.co/5cVgqfd4fX

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
🔍MRI lesions in early axSpA vs non axSpA with chronic back pain: -Data from SPACE cohort -n 318 (214 axSpA vs 108 non-axSpA). -Baseline imaging (CR and MRI) and at 2y f/u -Minimal progression on CR in both early axSpA and non-axSpA CBP. -On MRI, significant increase in the https://t.co/m5YOAiFUz1

Links:

Adela Castro @AdelaCastro222( View Tweet )
In 1314 PsA patients, cumulative methotrexate dose was not associated with liver fibrosis (OR 0.99). Instead, higher BMI (OR 1.03) & diabetes (OR 5.03) were key drivers. MASLD, not MTX, may underlie fibrosis risk in PsA. APRI >0.7 used for fibrosis detection. Abstract#POS0111 https://t.co/zsX7NUOT9m

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
Rheumatoid nodules are fascinating. If methotrexate nodulosis is a factor, why has their rate gone down when MTX use has gone up? Environmental factors? Something else? It’s still a bit of a mystery - we still don’t know why Christopher Edwards #EULAR2025 @RheumNow https://t.co/8LJYNRybve

Links:

David Liew @drdavidliew( View Tweet )
Acute Dactylitis in #Psoriatic_Arthritis 🔹️1216 patients Canada 🇨🇦 🔹️52% had at least one episode of acute dactylitis in a median 12 years 🔹️Positive association with HLA-B27 and HLA-B27/C02 🔹️No association with HLA-B51 #EULAR2025 @RheumNow OP0180 by Kharouf et al. https://t.co/oNNMBcvVb4

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
KORAIL cohort Prediction model for progression of RA-ILD at 3 years A combination of classic clinical parameters incl DA , ILD pattern, ACPA KL-6 with AUC 0.75 HR=34 for progression in High risk group Need validation in an external cohort @RheumNow #EULAR2025 OP0329 https://t.co/LIvn1JCXPq

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
pssfing.jpg

Predictors and Outcomes in Systemic Sclerosis

EurekAlert!

The VEDOSS project has previously shown that 70% of patients with Raynaud’s phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on nailfold capillaroscopy –will fulfil the 2013 ACR/EULAR SSc criteria within 5 years.

Read Article
LDCT to assess disease progression in early axSpA: -Data from SPACE cohort 67 pts (>50% male,>80% hLAB27+) - LDCT at baseline and 2 years apart. -Overall 22% pt with net disease progression. -Spine progression most frequent on thoracic spine. -Good reliability in assessing https://t.co/M2jkDusD41

Links:

Adela Castro @AdelaCastro222( View Tweet )
EULAR,poster

EULAR 2025 – Day 2 Report

Jack Cush, MD

Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options to rheumatologists. Here are a few

Read Article
Prédiction of PsA from PsO. Stockholm cohort, n=672): •PsA incidence 21.1/1000 PY. •AUC 0.80 for both referral and prognostic models. •Predictors: HLA-B27, uveitis, enthesial pain, TJC, hsCRP, BMI, SAA, GlycA. •Early identification feasible. Abstract OP0178 @RheumNow https://t.co/dxdChN6VZy

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
Do the sites of clinical onset of PsA (i.e., swelling) correspond to those that, at the time of enrollment in the study, showed evidence of joint tenderness and/or ultrasound-detected alterations compatible with inflammation? Of 28 incident PsA cases, 68% had prior subclinical https://t.co/rAZJU6Va5x

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
29% of new-onset psoriasis pts in Stockholm cohort developed PsA over 9,255 person-years. Two prediction models (AUC 0.804) identify: ➡ who to refer ➡ who will progress Key predictors: HLA-B27, CRP, enthesitis, arthralgia. @RheumNow #EULAR2025 #OP0178:

Jiha Lee @JihaRheum( View Tweet )

Multimodal data using clinical histological and serological predictors in renal function in #sle nephritis. Using the AMP SLE data. Low baseline eGFR and histological damage predicted worsening renal function but not NIH activity index #POS0173 #EULAR2025 @RheumNow @andreafa https://t.co/Eh8dZXHRVX

Links:

Bella Mehta @bella_mehta( View Tweet )
Tenosynovitis of 5th compartment independently associated w/ D2T RA in a cohort of 90+ pts compared to established RA Erosions, Tenosynovitis and Synovitis non associated with D2T phenotype It’d be interesting to see if this could predict D2T evolution in early RA pts POS0185 https://t.co/faruOr3HhJ

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
In #SLE, #HCQ levels >1150 ng/ml ↑toxicity risk w/o added benefit. Levels 750-1150 ng/ml linked to ↓disease activity. CKD stage ≥3 doubled HCQ levels at same dose. Supports monitoring & dose adjustment in CKD to balance safety & efficacy. @RheumNow #EULAR2025 #OP0199

Mrinalini Dey @DrMiniDey( View Tweet )

BioDMARDs reduce polyimmunity in RA Danish Registry based cohort study 5 yrs follow up 25000+ pts Polyimmunity in csDMARDs treated group 2.2% vs. 1.7% in bioDMARDs group HR 0.74 Most frequent autoimmune thyroid disease POS0161 #EULAR2025 @RheumNow https://t.co/9T0mhoUuqs

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
Leeds study of 223 ACPA+ Arthralgia pts w quant. MRI of hand showing tenosynovitis (34% at baseline) doubled the risk of progression to RA. Total tenosynovitis Volume = incr. RA risk #EULAR2025 POS0472 https://t.co/eT0wbhp1uN
Dr. John Cush @RheumNow( View Tweet )
Data from Dutch registry SpA-Net explored prevalence using new definitions for D2M axSpA. -Smoking and psoriasis were characteristics associated with D2M disease. -In the three variations explored, the lowest prevalence was observed in the variation based purely on objective https://t.co/h3f4ORQl0F

Links:

Adela Castro @AdelaCastro222( View Tweet )
Insights from the Gut-Joint Axis in axSpA: Findings from the DESIR cohort -Baseline biomarkers of bacterial translocation: PLTP (phospholipid transfer protein) and LPS evaluated. -In early axSpA baseline PLTP activity was associated with sacroiliac radiographic progression at 5

Adela Castro @AdelaCastro222( View Tweet )

Biomarker data suggest TNFi non-responders in PsA exhibit upregulation of IL-17F gene signatures after treatment failure. Supports IL-17A/F blockade rationale with bimekizumab in TNFi-experienced patients Abstract#OP0091 @RheumNow . #EULAR2025 https://t.co/CWR6ArDRRW

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
🔬 Proud to present our poster at #EULAR2025! 📌 Serum KL-6 and IL-18 as Diagnostic and Prognostic Biomarkers in Systemic Sclerosis-Associated ILD: A 24-Month Cohort Study KL-6 and IL-18 show promising roles in tracking ILD progression and lung function decline in #SSc 📍F.136 https://t.co/woTMnTkRKY

Links:

Cristiana Sieiro Santos @cristianasieiro( View Tweet )
Conv3.jpg

EULAR 2025 - Day 1 Report

Jack Cush, MD

Wednesday was Day One at EULAR 2025 in Barcelona. Thousands from around the world gathered, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.

Read Article
Got paraproteinemia? Here’s what to think about, from a rheumatology point of view. @RheumNow #EULAR2025 https://t.co/eu7Mi5yeum

Links:

David Liew @drdavidliew( View Tweet )
HLA-B27 Testing in Practice Analysis of testing for human leukocyte antigen B27 (HLA-B27) in a teaching center shows HLA-B27 testing was frequently performed by rheumatologists and nonrheumatologists for a broad spectrum of indications and primarily as a screening test. https://t.co/IabqHyi0rl
Dr. John Cush @RheumNow( View Tweet )
GCA,woman

Secukinumab Use in Refractory Giant Cell Arteritis

Jack Cush, MD

In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger phase 3 trial, there is a 6 patient case series also suggesting

Read Article

Recent Blogs

CNS Lupus (NPSLE)

Jack Cush, MD
Cush RhTh CNS
29 yr. old woman with SLE and transverse myelitis. Is this NPSLE; how to diagnose? Read Post

Unpopular opinion: spinach can be bad for you

Lara El Khoury, MD
pro con unsure opinion thumbs debate
PMR might be one of the most rewarding diagnoses to make in real practice: the patient comes to you in severe debilitating pain, and you prescribe steroids, giving them their lives back! As much as this impressive response makes your intervention appear almost magical, there is the often-forgotten story about the implications of such a diagnosis and treatment on patients' daily lives.  Read Post
×